What is the normal concentration of dasatinib?

Dasatinib (Dasatinib) is a tyrosine kinase inhibitor commonly used to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Monitoring of drug concentrations is important to ensure therapeutic efficacy and reduce side effects.

There is no universal standard for a reasonable concentration range for dasatinib because dose and concentration targets will vary based on individual patient circumstances and treatment goals. Normally, doctors will determine the dosage of dasatinib based on the patient's specific conditions and adjust the treatment plan by monitoring blood drug concentrations.

In patients with chronic myeloid leukemia, the therapeutic goal of dasatinib is to maintain a stable therapeutic response. According to research, it is appropriate to maintain the blood concentration of dasatinib between 100-350 ng/mL during the patient's stable period. However, this range is not absolute, and physicians will adjust dosage and concentration targets based on the patient's specific circumstances.

In addition to treatment monitoring during the stable period, dasatinib concentration monitoring is also very important for patients with treatment failure or resistance. If a patient experiences disease progression or adverse reactions during dasatinib treatment, doctors may recommend blood drug concentration monitoring and adjust the treatment plan based on the monitoring results.

In short, the reasonable concentration range of dasatinib should be determined by doctors based on the patient's specific conditions. If patients are receiving dasatinib treatment, it is recommended to have a detailed discussion with their doctor to understand the individualized treatment plan and the importance of blood concentration monitoring. Only under the guidance of a doctor can the safety and effectiveness of dasatinib be ensured.